我武生物(300357) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥369,123,847.45, representing a 22.64% increase year-over-year[5] - Net profit attributable to shareholders was ¥167,857,811.64, up 36.44% compared to the same period last year[5] - The basic earnings per share for the quarter was ¥0.3206, reflecting a 36.43% increase year-over-year[5] - Total operating revenue increased to ¥853,360,357.81, up from ¥730,238,304.07, representing a growth of approximately 16.83% year-over-year[18] - Net profit for the period reached ¥335,236,989.97, compared to ¥262,498,098.02 in the previous period, marking a growth of approximately 27.67%[19] - Total comprehensive income for the period attributable to the parent company was CNY 344,862,486.72, up from CNY 272,252,571.86 in the previous period, representing a growth of approximately 26.67%[20] - Basic and diluted earnings per share increased to CNY 0.6587 from CNY 0.5200, reflecting a rise of 26.54%[20] Assets and Equity - Total assets at the end of the reporting period amounted to ¥2,893,213,877.24, a 6.80% increase from the end of the previous year[5] - The company's total equity attributable to shareholders rose to ¥2,635,739,108.73, an increase of 11.98% from the previous year[5] - The company's total assets amounted to ¥2,893,213,877.24, an increase from ¥2,709,124,934.20, indicating a growth of about 6.79%[17] - The total equity attributable to shareholders increased to ¥2,635,739,108.73 from ¥2,353,706,702.01, reflecting a growth of approximately 11.97%[17] Cash Flow - Cash flow from operating activities increased by 79.11% to ¥286,891,077.51 year-to-date[10] - Cash inflow from operating activities totaled CNY 870,623,729.48, compared to CNY 643,008,995.35 in the previous period, marking an increase of 35.43%[20] - Net cash flow from operating activities was CNY 286,891,077.51, up from CNY 160,173,375.99, indicating a growth of 79.06%[20] - Cash inflow from investment activities was CNY 744,697,126.87, significantly higher than CNY 174,106,415.76 in the previous period, representing an increase of 327.36%[21] - Net cash flow from investment activities was -CNY 150,256,198.08, an improvement from -CNY 544,564,451.38, showing a reduction in cash outflow by 72.55%[21] - Cash inflow from financing activities was CNY 20,000,000.00, up from CNY 2,762,114.33, reflecting a growth of 624.57%[21] - Net cash flow from financing activities was -CNY 127,817,678.53, slightly worse than -CNY 120,336,902.70 in the previous period, indicating a marginal increase in cash outflow by 6.18%[21] Product Performance - The sales revenue from the "Dust Mite Drops" product was ¥794,221,951.72, a 13.38% increase year-over-year[9] - The revenue from "Artemisia Flower Pollen Sublingual Drops" surged by 117.58% to ¥44,756,599.93[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 32,427[12] - Zhejiang Wawu Management Consulting Co., Ltd. holds 38.86% of shares, totaling 203,454,131 shares[12] - The number of shares held by the top ten shareholders reflects significant concentration, with the top shareholder holding nearly 39%[12] Liabilities - Current liabilities decreased to ¥119,952,859.31 from ¥182,583,159.67, a reduction of approximately 34.29%[17] - Non-current liabilities decreased to ¥42,028,479.16 from ¥67,712,099.18, showing a decline of about 38.06%[17] Research and Development - The company completed a clinical trial for "Artemisia pollen allergen sublingual drops" in July 2025, providing evidence for long-term efficacy[13] - In August 2025, the company initiated a Phase I clinical study for "Dermatitis Diagnostic Patch 02" in Jining[13] - A Phase I clinical study for "Aspergillus niger puncture solution" was completed in September 2025, with a summary report obtained[13] Financial Position - The company's cash and cash equivalents decreased to ¥1,055,130,256.56 from ¥1,118,840,884.89[15] - Accounts receivable increased to ¥263,387,763.43 from ¥153,014,697.27[15] - The trading financial assets increased to ¥286,816,966.83 from ¥196,090,885.90[15] Audit Information - The company did not undergo an audit for the third quarter financial report[22]